Genome-wide association studies have identified genetic variants for thousands of diseases and traits. We evaluated the relationships between specific risk factors (for example, blood cholesterol level) and diseases on the basis of their shared genetic architecture in a comprehensive human disease-single-nucleotide polymorphism association database (VARIMED), analyzing the findings from 8962 published association studies. Similarity between traits and diseases was statistically evaluated on the basis of their association with shared gene variants. We identified 120 disease-trait pairs that were statistically similar, and of these, we tested and validated five previously unknown disease-trait associations by searching electronic medical records (EMRs) from three independent medical centers for evidence of the trait appearing in patients within 1 year of first diagnosis of the disease. We validated that the mean corpuscular volume is elevated before diagnosis of acute lymphoblastic leukemia; both have associated variants in the gene IKZF1. Platelet count is decreased before diagnosis of alcohol dependence; both are associated with variants in the gene C12orf51. Alkaline phosphatase level is elevated in patients with venous thromboembolism; both share variants in ABO. Similarly, we found that prostate-specific antigen and serum magnesium levels were altered before the diagnosis of lung cancer and gastric cancer, respectively. Disease-trait associations identify traits that could serve as future prognostics, if validated through EMR and subsequent prospective trials.
INTRODUCTION
Genome-wide association studies (GWAS) and candidate gene approaches have identified genetic variants for thousands of traits (1) (2) (3) . Studied traits included clinical measurements (for example, cholesterol levels), social behavior (for example, smoking), patient characteristics (for example, weight), and disease susceptibility. At the same time, the number of GWAS performed to study diseases has rapidly increased since 2007, and their findings provide opportunities to investigate the potential impact of common genetic variants on complex diseases (4, 5) . It has already been noted that seemingly different diseases and conditions that share associated single-nucleotide polymorphisms (SNPs) may have common biological mechanisms (6, 7) .
With so many successful GWAS already completed on nondisease traits (referred hereafter as traits), we hypothesized that diseases and traits could be similarly related to each other through shared genetic variation. Preliminary work by us (8) and others (5) suggests that traits could indeed share variants with diseases. There could be high value in such a disease-trait association for medicine if the trait is easily or cheaply measured, or is already commonly measured in health care setting, and if the trait can be identified before the disease.
We hypothesized that traits could serve as potential new prognostic markers or risk factors for disease susceptibility, if those traits significantly shared genetic associations with diseases. We theorized that if variant-associated genes found in a GWAS of traits significantly matched gene variants found associated with a disease, those traits might be predictive for diseases, especially if that trait was one already measured in a clinical care settings, already captured in an electronic medical record (EMR).
RESULTS

Genes associated with diseases and traits
This study reports a method for predicting new markers for disease from genetic associations found for thousands of diseases and traits from GWAS. We started with findings from VARIMED (VARiants Informing MEDicine) (9-13), a manually curated database of disease-SNP associations, containing more than 100 features of association studies from 8962 human genetics papers covering 2376 diseases and traits. VARIMED has been used to interpret the genome sequences of patients and other individuals (9, 14) . We identified a list of disease-trait pairs based on shared genetic architecture. Figure 1 shows our overall experimental design. From VARIMED, we identified significant associations between 801 unique genes and 69 diseases (median = 10 per disease), and between 796 unique genes and 85 traits (median = 10 per trait). In each case, there were at least three significant genes per disease or trait, and the P value was <1 × 10 −8 at the genome-wide significance level from individual GWAS (table S1, A and B). The three diseases with the most associated genes were rheumatoid arthritis (122 genes), membranous nephropathy (88 genes), and myocardial infarction (73 genes) . The top 3 traits with the most associated genes were height (120 genes), blood cholesterol level (50 genes), and blood protein C levels (49 genes). We plotted the distributions of the gene counts as a density map by kernel density estimation (fig. S1A). We found no significant difference between the distribution of gene-disease associations and gene-trait associations via the Kolmogorov-Smirnov test (P = 0.16). We concluded that the number of genes associated with either traits or diseases was unbiased and comparable.
Disease and trait associations identified by shared variant-associated gene We searched for pairs of diseases and traits that shared variants in common genes. To evaluate the significance of the association, we assigned an information content measure to each gene on the basis of how frequently a gene was associated across diseases and traits using term frequencyinverse document frequency (TF-IDF), and then controlled for multiple hypothesis testing by random shuffling 1000 times. We identified 120 disease-trait pairs significant at q ≤ 0.01 based on the pairwise cosine distance calculation (see Materials and Methods). Among the 120 pairs, 96 (80%) pairs linked a disease and trait that were originally published in different GWAS or candidate gene studies (table S2) . Forty-five unique diseases and 50 unique traits were identified out of the 120 significant disease-trait pairs. To evaluate the accuracy of our predictions, we manually reviewed the biomedical literature to see if we could corroborate these 120 predicted associations. Ninety-four pairs were known, published associations between diseases and traits. Twenty-six pairs were previously undescribed, without previous evidence in the literature (table S2) . We plotted the distribution of the PubMed counts for shared genes for disease-trait pairs. We found no significant difference between the distribution of the number of published human genetic papers in genes shared in known and newly discovered disease-trait pairs via the Kolmogorov-Smirnov test (P = 0.51) (fig. S1B).
Genetic commonality between diseases and traits
We generated a comprehensive network for visualizing all 120 diseasetrait pairs ( Fig. 2 and table S2 ). Diseases (blue circles) and traits (orange triangles) were connected to each other by edges when there was a significant association at q ≤ 0.01. If multiple diseases or traits were connected to the similar traits or diseases, these were grouped into super sets (termed "modules"), simplifying the visualization of this complex network. Eight major disease modules (blue circles) were revealed in the network, which represent groups of diseases sharing a significant genetic association to a particular trait or a group of traits.
Four modules presented known classifications based on the physiological system affected by the disorder. For instance, solid organ cancer (Fig. 2 , module D1) was connected with prostate-specific antigen (PSA) levels because this trait and these diseases were significantly associated through TERT. The skin cancer module (Fig. 2 , module D2) was connected with pigmentary characteristics, as a trait, through SLC45A2 or MC1R. The autoimmune disorder module (D6) was connected with antibody titer levels through association with major histocompatibility complex (MHC) class I/II or MHC class-related molecules. Finally, type 2 diabetes-related syndromes (Fig. 2 , module D3) were connected with proinsulin levels. Most of these connections were through ARAP1, MADD, or TCF7L2 (table S2) .
The remaining four disease modules (Fig. 2, D4 , D5, D7, and D8) exhibited multiple-to-multiple relationships underlying unexpected shared genetic commonality. One module (Fig. 2 , module D4) connected esophageal cancer and alcohol dependence with cholesterol levels through ALDH2, BRAP, and C12orf51, whereas another (Fig. 2 , module D5) connected Kawasaki disease and chronic obstructive pulmonary disease (COPD) with smoking through RAB4B.
We identified seven trait modules (Fig. 2, T1 to T7, orange circles). Three modules had known associations: pigmentary characteristics (Fig. 2, T1 ) with skin cancer (D2) through MC1R or SLC45A2, and a subset (freckles and eye colors) with chronic lymphocytic leukemia through IRF4. Coagulation factor activity tests (Fig. 2, T4 ) were connected with venous thromboembolism (VTE). Three were related through ABO (table S2) . Lipid panel (Fig. 2, T5 ) was connected through APOC1, APOE, PVRL2, and TOMM40 to Alzheimer's disease, through CELSR2, LDLR, PSRC1, and ZNF259 to coronary artery disease (CAD), and through ZNF259 to metabolic syndrome.
Detecting traits known to be associated with diseases Ninety-four of the 120 significant disease-trait associations were known findings supported by published studies (table S2); these disease-trait associations could be classified into one of three types based on the temporal relationship between the trait and disease pathogenesis: (i) risk factors, for which traits manifest before disease onset and may cause the disease; (ii) diagnostic tests, for which traits manifest contemporaneously with disease onset; and (iii) consequences or complications, for which traits manifest after the disease diagnosis ( Fig. 3 and table S2 ). We manually categorized each known finding into one of these three categories on the basis of original clinical studies ( were shared between smoking and COPD: AGPHD1, CHRNA3, and RAB4B ( Fig. 2 and table S2 ). The COPD patients in all six GWAS were former or current smokers (15) (16) (17) (18) (19) (20) . Smoking is the primary risk factor for COPD (21) (22) (23) , and little is known about the nature of the inflammatory response leading to the pathogenesis of COPD (21) . Therefore, of the six genetic variants previously discovered and published to be associated with COPD, these three might have been indirectly influenced by smoking (concept illustrated in Fig. 3 ) and might actually reflect variants related to smoking (that is, propensity to addiction, noncessation, and variable action of nicotine).
Existing diagnostic tests were also reidentified through our approach. In one GWAS, 21 genes were associated with antibody titer levels after inoculation with hepatitis B vaccine (24) . However, this study did not include patients with autoimmune diseases. We found that antibody titer levels, as a trait, were significantly associated with 16 autoimmune diseases. Antinuclear antibody and autoantibody tests can serve as diagnostic tests in autoimmune disorders and diseases (table S2 and Fig. 2 ). Although the GWAS (24) did not explicitly enroll participants with these autoimmune diseases, our method inferred known relationships between clinical measurements, such as autoantibody tests, and autoimmune diseases on the basis of their shared genetic architecture (Fig. 3) .
Last, among the 28 known pairs reflecting comorbidity or consequence (table S2) , alcohol dependence syndrome (ADS) was associated with three traits: cholesterol levels through shared variants in ALDH2, BRAP, and C12orf51; alanine aminotransferase (ALT) levels through shared variants in C12orf51; and high-density lipoprotein cholesterol (HDL-C) levels through shared variants in C12orf51 and OAS3. In this case, we speculate that the three genes found associated with cholesterol levels reported by Kato et al. (25) and two genes for ALT and HDL-C reported by Kim et al. (26) were discovered in cohorts containing individuals who might have been influenced by alcohol, although these authors did not control for any alcohol effect in their GWAS investigations on these genes (25) (26) (27) . In addition, high HDL-C has been previously observed with triple frequency in individuals with ADS (28) . Further, a high cholesterol content diet has been found in patients with ADS (29) . ALT levels are associated with increased daily alcohol intake in individuals with ADS (30) .
Clinical validation of previously undescribed disease-trait pairs with EMR To evaluate our new associations between traits and diseases, we obtained EMR data, because they represented a patient cohort independent from our curated GWAS studies. We obtained deidentified EMR data from three independent clinical centers: Stanford Hospital and Clinics (SHC) (31), Mount Sinai Medical Center (MSMC), and Columbia University Medical Center (CUMC). Among 26 new disease-trait pairs, we studied 5 that could be validated solely by electronic means based on clinical data available in the three centers. In addition, we tested a positive control disease-trait pair, and two nonrelated disease-trait pairs as negative controls.
Our first new pair was that mean corpuscular volume (MCV) and acute lymphoblastic leukemia (ALL) were both associated with IKZF1 (q = 0.001; Table 1 ]. Just as with the previous findings, the PSA values were significantly higher in those diagnosed with LCA within 1 year before our first diagnosis compared to all other PSA measurements (P = 0.002 and 0.028 for SHC and MSMC, respectively; Fig. 4C ).
We similarly validated our fourth finding, alkaline phosphatase (ALP) level related to VTE through ABO and TERT (q = 0.008; at SHC, P = 2.47 × 10 −43 at MSMC, and P = 2.67 × 10 −6 at CUMC; Fig. 4E ). To evaluate whether the significance of our five validated diseasetrait pairs was confounded by age and gender, we adjusted age and gender variables in a logistic regression model for each of these five tests. We discovered that significant associations still persisted for MCV and ALL [adjusted OR, 3.5 (95% CI, 3.02 to 4.14), with P < 2 × at CUMC; fig. S2A ).
We also tested two nonrelated associations as negative controls (PSA and ALL or GCA) using data from SHC. For the two negative control experiments, we performed the same tests, and we did not observe an association between laboratory values and disease ( fig. S2 , B and C, and Table 1 ).
DISCUSSION
We have developed a systematic approach for identifying genetic associations between traits and disease susceptibilities through shared genetic architecture. The goal was to identify traits as potential disease prognostic markers or risk factors. We identified 120 disease-trait pairs for traits associated with diseases; 80% of the pairs linked a disease and trait that had been published in distinct GWAS. Ninety-four had previous evidence in the literature, whereas 26 disease-trait pairs were newly described. We showed that these predicted relationships can be tested using medical center EMRs, when sufficient numbers of patients have data with assessments of both the trait and disease. We validated the relationships for five previously unreported findings-MCV to ALL, MGN to GCA, ALP to VTE, PSA to LCA, and PLT to ADS-using independent clinical EMR data from three independent academic medical centers.
The network representation for the significant 120 disease-trait pairs enabled us to highlight the complex genetic relationships between diseases and traits. The network revealed interconnections within and across eight disease modules and seven trait modules. Diseases and traits with shared genetic architecture can point to new markers and, potentially, therapeutic intervention and monitoring strategies. We noted that the traits and diseases associated with the most genes did not have more connections than diseases or traits with fewer gene associations, suggesting an accurate prioritizing strategy.
The strength of our strategy is that this approach can connect diseases and traits across the nosology or taxonomy of diseases. Another strength is that it provides a tractable framework that enables initial steps toward the development or redefinition of human disease nomenclatures informed by genetic variation. This gives the method potential utility in clinical care.
We found interesting relationships even with this known set of 94 relations beyond behavioral risk factors and diseases themselves. Examples include shared architecture for smoking and COPD, as well as ALT levels and alcohol dependence. For instance, because COPD commonly results from smoking, variants that have been discovered and associated with COPD could be influenced by smoking; the true genetic variants for COPD might only be unmasked if the smoking variable is controlled for in COPD GWAS. Similarly, the association of the four genetic variants with ALT, cholesterol, and HDL-C could be biased by the effect of alcohol. The GWAS to identify concrete genetic variants for these three clinical measurements should be performed in patients, ensuring that alcohol dependence is not a confounder. Thus, our study indicates that some findings from GWAS may have been influenced by or resulted from subject behaviors.
In addition, although we focus on disease-trait association in this study, a disease could be the potential confounder to another disease as well. For instance, ADS is a risk factor to HDL-C, which is a known risk factor to CAD (32) , and C12orf51 was shared among them; therefore, C12orf51 variants associated with CAD could be confounded by ADS. Similarly, metabolite levels, such as MGN levels, are distorted in severe gastrointestinal disorders, and these disorders might actually be the causal factor for patients with subsequent diagnosis of another disease. We suggest that known and newly discovered risk factors should be considered in future GWAS design to properly identify variants more independent of behavioral or environmental influence (33, 34) . Lack of full consideration of behavioral risk factors and their interaction with the genome may be one explanation of the small effect sizes or ORs (1.1 to 1.5) in published GWAS (35) , although this is speculation.
Causal relationships between risk factors and disease are difficult to determine. However, investigators can now use genetic information to ascertain causality between risk factors and disease in an observational study (for example, HDL-C and cardiovascular disease) by using Mendelian randomization (36) (37) (38) . Mendelian randomization is a method of using measured variation in genes of known function to examine the causal effect of a modifiable (nongenetic) exposure on disease in nonexperimental studies in epidemiology. If a trait exists on the causal pathway for disease, carriers of genetic variants associated with abnormal levels of the trait would be expected to be at different risk for disease. For example, Voight and colleagues have cast doubt on whether higher level of HDL-C is connected with a lower risk for myocardial infarction (39). The method described here provides a way of predicting relationships between traits and diseases, complementing Mendelian randomization. Predictions arising from similarity in genetic architecture such as the ones we have reported here may be tested in subsequent studies by using Mendelian randomization.
Another strategy to test predicted disease-trait associations is to use information from EMR, a resource that can provide patient phenotypic and physiological measurements, in the context of the clinical care setting, even before the diagnosis of disease (40, 41) . We used this approach here to validate five of our newly described disease-trait pairs. Our results show that these five clinical measurements can be risk factors for their paired diseases. This method could be expanded to cover larger and smaller units of time, or more distant time frames, as well as to take age into account.
Nevertheless, associations between complex traits and diseases discovered via genetic similarity and subsequent EMR-based retrospective validation cannot fully distinguish the causal relationships between traits and diseases. GWAS inherently capture only common variants, and consequently, certain associations between diseases and traits could be missing in our approach. In a tertiary care hospital setting, it is not always clear when and where the first diagnosis of disease took place by just looking at EMR data. We do not always know if a patient had been diagnosed elsewhere or how long the patient has had a disease before their first observed diagnosis at each medical center. (The median onset age was correlated with known average ages of onset of each disease, suggesting that most of these patients did not receive care for any significant period of time elsewhere before presenting to a hospital setting.) ICD-9 (International Classification of Diseases, 9th Revision) codes also may not be clear enough for specific phenotype identification. That being said, we speculate that the codes we used for cancers are more likely to be accurately assigned than those for obesity and less severe disorders. Although methods for phenotyping from the eMERGE (42) project could have been deployed to reduce misclassification, the phenotypes we studied here were not yet listed in PheKB (42) .
Laboratory values and measurements can be influenced by other related diseases or conditions and comorbidities. We did not control for these effects because there is no well-documented list of potential confounders for every laboratory measurement; however, we assumed that cases and controls were matched by a common set of characteristics. Additionally, it has been shown that hospitalized patients make poor control subjects, a phenomenon described as the Berkson bias, where a noncausal association exists between exposure and disease because of the condition that the subject has to come to the hospital to be involved in the study (43) . Each individual relationship described through shared genetic architecture should be further tested in prospective epidemiology studies.
Here, we had also desired to evaluate the rest of the predicted diseasetrait pairs. For instance, PSA was associated with testicular cancer (TCA), through CLPTM1L and TERT (q < 0.001; table S2). However, because the disease incidences were low at all three centers (only 22 at SHC, 33 at MSMC, and 65 patients at CUMC had PSA laboratory values measured before the first diagnosis for TCA), we did not have sufficient power to perform such analysis. Another finding was bone mineral density related to sudden cardiac arrest through the ESR1 gene. Validation of findings such as these may be possible by using public health and longitudinal study data. Future studies to validate disease-trait pairs may require linking the EMR of multiple centers to gain the necessary numbers of patients needed.
In conclusion, investigation of traits that share genetic architecture with a disease and validating them through EMR is a powerful way to identify risk factors and prognostics. These associated traits show that risk factors need to be better considered or controlled in GWAS design to identify independent variants without the confounding of behavioral, environmental, or informative disease pathophysiology. Whether these traits can serve as diagnostic markers for complex diseases will depend on prospective trials.
MATERIALS AND METHODS
Extracting diseases and traits from VARIMED As of this writing, VARIMED is a database of SNPs and diseases obtained from the manual review of 8962 human genetics papers including GWAS and candidate gene studies, with 87,553 SNPs mapped to 8913 genes and 1119 diseases and 1256 traits. We considered only diseases and traits whose genetic variants had genome-wide significance (P < 1 × 10
) (44) . Using this filter, we identified 201 diseases and 249 traits with at least one variant that mapped to a genic region. All genetic variants were then systematically mapped to genes with the most recent National Center for Biotechnology Information Entrez Gene identifiers through Entrez dbSNP using AILUN (45) . SNPs in intergenic regions could not be associated with specific genes and were not considered. Next, to capture only highly relevant associations for enrichment, we kept only diseases and traits associated with at least three genes, yielding 69 diseases and 85 traits associated with 1439 genes. Distributions for the number of genes associated with diseases and traits were evaluated with Kolmogorov-Smirnov test (fig. S1A ).
TF-IDF weighting scheme for shared genetic architecture between diseases and traits For each gene associated with a disease or trait, we computed the gene popularity using the TF-IDF weighing method (46) to down-weight the ubiquitous genes that are associated with many diseases. For instance, LPL is associated with seven diseases/traits, whereas CR1 is associated only with two diseases/traits (table S2). The detailed TF-IDF (46) calculation procedure for all 5865 combinations of disease-trait pairs (69 × 85) with 8913 genes is described as follows. First, we calculated a TF using TF ði, jÞ ¼
, where n i, j is the number of occurrences of gene i in a particular disease or trait j. ∑ k n k, j indicates the total number of occurrences of all genes in a particular disease or trait j. The value of TF (i, j) indicates the level of occurrence frequency of gene i in disease or trait j. Next, we calculated IDF using IDF ðiÞ ¼ log 10 ð
Þ. Here, D is the total number of diseases and traits, and D i is the number of disease and trait containing gene i. A larger IDF (i) implies a lower popularity of gene i among the diseases or traits, translating into more weight because it might only be shared between these two phenotypes among 8913 genes. Last, we calculated a TF-IDF score using TF − IDF ði, jÞ ¼ TF ði, jÞ Â IDF ðiÞ for each gene within individual disease or trait by taking into account the popularity of the gene.
Assessing significance of disease-trait distance via the false discovery rate (q value) We then calculated the false discovery rate (q value) to control for multiple-hypothesis testing and assess significance of similarity between diseases and traits. A q value (47) is an estimate of the rate of false positives incurred at a given significance threshold. Disease-trait similarity was estimated using the cosine distance between TF-IDF (i, j) scores for all disease-trait combinations (equation as follows, where D and T are disease or trait and i is the gene shared between them).
Next, to evaluate the significance of a disease-trait distance score, we randomly shuffled the genes across all the traits and recomputed the disease-trait distance. We repeated the randomization procedure 1000 times to estimate the null distribution of the cosine distance for each pair. The q values were calculated as the ratio of the expected number of false positives over the total number of hypotheses tested (47) . A q value of ≤0.01 was chosen as a significant association level between disease-trait pairs. Distributions for the number of PubMed counts reported for shared genes in known versus new discovered disease-trait pairs were evaluated with Kolmogorov-Smirnov test (fig. S1B ).
Network visualization of the significant disease-trait pairs
We visualized a network representation of the disease-trait pairs identified as significant. We used Cytoscape 2.6.0 (48) and the CyOog (49) plug-in to represent and visualize the modular nature of the network, using all default settings. Diseases connected to the same trait were grouped into a super set (termed modules), as were traits connected to the same diseases. Each edge indicates a minimum significant association with q ≤ 0.01; edge formation was not based on Cytoscape or CyOog.
Using EMR from three independent medical center database systems We used adult patient EMR data from three medical centers after 1 January 2005 as independent cohorts to validate our findings. We identified case groups with the first diagnoses of target diseases using ICD-9 diagnosis codes: 204.0 for acute lymphoid leukemia (ALL), 303 for ADS, 151 for GCA, 186 for TCA, 162 for LCA, 453 for VTE, and 185 for PCA. The control group for each analysis was taken from the adult patients without the diagnosis of target disease. Reference ranges for laboratory tests were based on MedlinePlus from the National Library of Medicine. They were as follows: serum/plasma PLT count, 150 to 400 K/ml; serum/ plasma MGN, 1.8 to 2.4 mg/dl; MCV, 82 to 98 fl; ALP, 44 to 147 IU/liter; and PSA, <4 ng/ml.
Validation of newly described disease-trait pairs with EMR data
Use of EMR data was approved by individual's Institutional Review Board. To perform c 2 tests, laboratory values were discretized. Values outside the reference range were defined as being in the "abnormal range." Values less than the low reference was defined as "low range," and those greater than the high reference were "high range." For a given test, we compared the maximum and minimum laboratory values to the reference range if multiple tests had been performed on a patient during the analysis time frame, which was defined as 1 year before disease diagnosis. Patients were defined as normal if laboratory results were within reference ranges, and abnormal if they were high or low range. Patients were excluded if multiple laboratory values were both high and low range.
We performed Wilcoxon rank-sum test by evaluating the actual laboratory values and c 2 tests by calculating the ORs for abnormal ranges versus normal reference range between case and control groups. We report the ORs along with 95th percentile confidence intervals and P value. We compared the percentage of abnormal results for case and control patients 1 year before our first diagnosis code of the target disease in case patients, and in control patients who were cared for at SHC, MSMC, and CUMC and without diagnosis of target disease. This allowed us to investigate whether changes in laboratory values could be risk factors for predicting case incidence. In addition, logistic regression using generalized linear model function was also performed by adjusting age and gender variables in each prediction model, and the adjusted OR was also reported.
All statistics were computed by SAS 9.2 (SAS Institute) and R 2.15.1 (50) .
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